Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial.
作者信息
Bucci Enrico M, Berkhof Johannes, Gillibert André, Gopalakrishna Gowri, Calogero Raffaele A, Bouter Lex M, Andreev Konstantin, Naudet Florian, Vlassov Vasiliy
机构信息
Sbarro Institute, Temple University Department of Biology, Philadelphia, 19122 PA, USA.
Department of Epidemiology and Data Science, Amsterdam University Medical Centers, Amsterdam, Netherlands.
出版信息
Lancet. 2021 May 22;397(10288):1881-1883. doi: 10.1016/S0140-6736(21)00899-0. Epub 2021 May 12.
Abstract
摘要
相似文献
1
Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial.
Lancet. 2021 May 22;397(10288):1881-1883. doi: 10.1016/S0140-6736(21)00899-0. Epub 2021 May 12.
2
Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial - Authors' reply.
Lancet. 2021 May 22;397(10288):1883-1884. doi: 10.1016/S0140-6736(21)00894-1. Epub 2021 May 12.
3
Mild Adverse Events of Sputnik V Vaccine in Russia: Social Media Content Analysis of Telegram via Deep Learning.
J Med Internet Res. 2021 Nov 29;23(11):e30529. doi: 10.2196/30529.
4
BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19.
Front Immunol. 2022 Apr 13;13:797918. doi: 10.3389/fimmu.2022.797918. eCollection 2022.
5
ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance.
EClinicalMedicine. 2021 Jul 8;38:101027. doi: 10.1016/j.eclinm.2021.101027. eCollection 2021 Aug.
6
Sputnik Light and Sputnik V Vaccination Is Effective at Protecting Medical Personnel from COVID-19 during the Period of Delta Variant Dominance.
Vaccines (Basel). 2022 Oct 26;10(11):1804. doi: 10.3390/vaccines10111804.
7
Kinetics of Antibody Response to Repeated Vaccination with Sputnik V: A Pilot Study with a Series of Five Cases.
EJIFCC. 2022 Aug 8;33(2):175-186. eCollection 2022 Aug.
8
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2.
9
International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.
J Nucl Med. 2013 May;54(5):683-90. doi: 10.2967/jnumed.112.110890. Epub 2013 Mar 20.
10
Adverse effects following COVID-19 vaccination in Iran.
BMC Infect Dis. 2022 May 18;22(1):476. doi: 10.1186/s12879-022-07411-5.
引用本文的文献
1
Determinants of COVID-19 Vaccine Uptake Among People Living with Human Immunodeficiency Virus.
J Int Assoc Provid AIDS Care. 2025 Jan-Dec;24:23259582251328861. doi: 10.1177/23259582251328861. Epub 2025 Apr 1.
2
How prevalent is COVID-19 vaccine hesitancy in low-income and middle-income countries and what are the key drivers of hesitancy? Results from 53 countries.
BMJ Open. 2023 Nov 6;13(11):e069152. doi: 10.1136/bmjopen-2022-069152.
3
Development of Peptic Ulcer following Second Shot of Sputnik V Vaccine: A Case Report and Literature Review of Rare Side Effects of Sputnik V Vaccine.
Case Rep Infect Dis. 2023 Sep 21;2023:9989515. doi: 10.1155/2023/9989515. eCollection 2023.
4
Adverse events following immunisation with the first dose of sputnik V among Iranian health care providers.
Clin Exp Vaccine Res. 2023 Jan;12(1):25-31. doi: 10.7774/cevr.2023.12.1.25. Epub 2023 Jan 31.
5
Efficacy and safety of COVID-19 vaccines.
Cochrane Database Syst Rev. 2022 Dec 7;12(12):CD015477. doi: 10.1002/14651858.CD015477.
6
Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study.
BMC Med. 2022 Sep 20;20(1):312. doi: 10.1186/s12916-022-02509-8.
7
COVID-19: The question of genetic diversity and therapeutic intervention approaches.
Genet Mol Biol. 2022 Apr 8;44(1 Suppl 1):e20200452. doi: 10.1590/1678-4685-GMB-2020-0452. eCollection 2021.
8
Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Restimulation.
Front Immunol. 2022 Feb 24;13:840707. doi: 10.3389/fimmu.2022.840707. eCollection 2022.
9
Mild Adverse Events of Sputnik V Vaccine in Russia: Social Media Content Analysis of Telegram via Deep Learning.
J Med Internet Res. 2021 Nov 29;23(11):e30529. doi: 10.2196/30529.
10
The clinical correlates of vaccine-induced immune thrombotic thrombocytopenia after immunisation with adenovirus vector-based SARS-CoV-2 vaccines.
Immunother Adv. 2021 Aug 17;1(1):ltab019. doi: 10.1093/immadv/ltab019. eCollection 2021 Jan.
本文引用的文献
1
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2.
2
Safety and efficacy of the Russian COVID-19 vaccine: more information needed - Authors' reply.
Lancet. 2020 Oct 3;396(10256):e54-e55. doi: 10.1016/S0140-6736(20)31970-X. Epub 2020 Sep 21.
3
Safety and efficacy of the Russian COVID-19 vaccine: more information needed.
Lancet. 2020 Oct 3;396(10256):e53. doi: 10.1016/S0140-6736(20)31960-7. Epub 2020 Sep 21.
4
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Lancet. 2020 Sep 26;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3. Epub 2020 Sep 4.
Zotero 插件